An advanced phase of chronic myelogenous leukemia. It is characterized by: 1. the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for blast phase chronic myelogenous leukemia is limited due to its relatively rare occurrence and the complexity of its clinical presentation. As this condition affects fewer individuals, systematic clinical studies have been sparse, leading to gaps in our understanding of its genetic basis and clinical features. Ongoing research aims to address these gaps, providing hope for better characterization and management in the future.
To navigate your care effectively, consider seeking a hematologist with expertise in chronic myelogenous leukemia, specifically someone familiar with blast phase management. Engaging with clinical trials may also be beneficial, as they can provide access to cutting-edge therapies. For additional resources, visit the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers support and information for rare disease patients. While there are no specific patient organizations identified for this condition, participating in clinical trials can connect you with other patients and researchers.
There are several FDA-approved orphan drugs for blast phase CML, including nilotinib, dasatinib, and asciminib. Additionally, there are ongoing clinical trials investigating new therapies, with 23 active studies currently listed. You can explore these trials at ClinicalTrials.gov using the following link: https://clinicaltrials.gov/search?cond=blast%20phase%20chronic%20myelogenous%20leukemia%2C%20BCR-ABL1%20positive. This research landscape provides a pathway for potential new treatment options.
Actionable guidance for navigating care for blast phase chronic myelogenous leukemia, BCR-ABL1 positive
To navigate your care effectively, consider seeking a hematologist with expertise in chronic myelogenous leukemia, specifically someone familiar with blast phase management. Engaging with clinical trials may also be beneficial, as they can provide access to cutting-edge therapies. For additional resources, visit the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers support and information for rare disease patients. While there are no specific patient organizations identified for this condition, participating in clinical trials can connect you with other patients and researchers.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for blast phase chronic myelogenous leukemia is limited due to its relatively rare occurrence and the complexity of its clinical presentation. As this condition affects fewer individuals, systematic clinical studies have been sparse, leading to gaps in our understanding of its genetic basis and clinical features. Ongoing research aims to address these gaps, providing hope for better characterization and management in the future.
To navigate your care effectively, consider seeking a hematologist with expertise in chronic myelogenous leukemia, specifically someone familiar with blast phase management. Engaging with clinical trials may also be beneficial, as they can provide access to cutting-edge therapies. For additional resources, visit the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers support and information for rare disease patients. While there are no specific patient organizations identified for this condition, participating in clinical trials can connect you with other patients and researchers.
There are several FDA-approved orphan drugs for blast phase CML, including nilotinib, dasatinib, and asciminib. Additionally, there are ongoing clinical trials investigating new therapies, with 23 active studies currently listed. You can explore these trials at ClinicalTrials.gov using the following link: https://clinicaltrials.gov/search?cond=blast%20phase%20chronic%20myelogenous%20leukemia%2C%20BCR-ABL1%20positive. This research landscape provides a pathway for potential new treatment options.
Actionable guidance for navigating care for blast phase chronic myelogenous leukemia, BCR-ABL1 positive
To navigate your care effectively, consider seeking a hematologist with expertise in chronic myelogenous leukemia, specifically someone familiar with blast phase management. Engaging with clinical trials may also be beneficial, as they can provide access to cutting-edge therapies. For additional resources, visit the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers support and information for rare disease patients. While there are no specific patient organizations identified for this condition, participating in clinical trials can connect you with other patients and researchers.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for blast phase chronic myelogenous leukemia is limited due to its relatively rare occurrence and the complexity of its clinical presentation. As this condition affects fewer individuals, systematic clinical studies have been sparse, leading to gaps in our understanding of its genetic basis and clinical features. Ongoing research aims to address these gaps, providing hope for better characterization and management in the future.
To navigate your care effectively, consider seeking a hematologist with expertise in chronic myelogenous leukemia, specifically someone familiar with blast phase management. Engaging with clinical trials may also be beneficial, as they can provide access to cutting-edge therapies. For additional resources, visit the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers support and information for rare disease patients. While there are no specific patient organizations identified for this condition, participating in clinical trials can connect you with other patients and researchers.
There are several FDA-approved orphan drugs for blast phase CML, including nilotinib, dasatinib, and asciminib. Additionally, there are ongoing clinical trials investigating new therapies, with 23 active studies currently listed. You can explore these trials at ClinicalTrials.gov using the following link: https://clinicaltrials.gov/search?cond=blast%20phase%20chronic%20myelogenous%20leukemia%2C%20BCR-ABL1%20positive. This research landscape provides a pathway for potential new treatment options.
Actionable guidance for navigating care for blast phase chronic myelogenous leukemia, BCR-ABL1 positive
To navigate your care effectively, consider seeking a hematologist with expertise in chronic myelogenous leukemia, specifically someone familiar with blast phase management. Engaging with clinical trials may also be beneficial, as they can provide access to cutting-edge therapies. For additional resources, visit the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers support and information for rare disease patients. While there are no specific patient organizations identified for this condition, participating in clinical trials can connect you with other patients and researchers.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.